Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
CLEO Diagnostics Ltd ( (AU:COV) ) has provided an announcement.
Cleo Diagnostics Ltd is advancing its ovarian cancer diagnostic test with ongoing U.S. clinical trials and expanded Australian trials. The company remains on track for FDA submission and is enhancing its product development and stakeholder engagement strategies. With a cash reserve of A$7.311M, Cleo Diagnostics is strategically positioning itself for market entry and potential growth.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is a company specializing in ovarian cancer diagnostics, primarily through the development of a simple and accurate blood test for early detection. The company is focused on expanding its market presence, particularly in the U.S., and is engaged in ongoing clinical trials to validate its diagnostic test for this market.
YTD Price Performance: -1.39%
Average Trading Volume: 60,885
Technical Sentiment Consensus Rating: Sell
Find detailed analytics on COV stock on TipRanks’ Stock Analysis page.